Response to "Comment on 'recent trends of LDL-C control and lipid-lowering therapy in patients with ASCVD in Taiwan: 2015-2020" [0.03%]
“台湾ASCVD患者LDL-C控制和降脂治疗近期趋势(2015-2020年)”一文的回信
Yu-Chung Hsiao,Tzu-Yang Chen,Fang-Ju Lin et al.
Yu-Chung Hsiao et al.
Comment on "Satisfaction with bladder management in community-dwelling patients with chronic spinal cord injury" [0.03%]
关于“慢性脊髓损伤社区患者的膀胱管理满意度”的评论
Junwei Feng,Han Zhang,Chen Chen et al.
Junwei Feng et al.
Response to the comment on"Molecular genetic analysis of two novel ABO∗A alleles causing Ax phenotype in Chinese" [0.03%]
对“中国人两例新型ABO*A基因型导致Ax表型的分子遗传分析”一文的答复
Hang Lei,Can Lou,Xiaohong Cai
Hang Lei
Response to comment on "Perioperative copeptin elevations and prediction of myocardial injury and acute kidney injury after abdominal surgery: A preliminary prospective observational study": Prediction or cardiovascular stress response? [0.03%]
对《术前copeptin升高及预测腹腔手术后心肌损伤和急性肾损伤:初步前瞻性观察研究》一文的评论及回复:预测或心血管应激反应?
Yi-Ping Wang,Ko-Lin Wu,Ming-Hui Hung
Yi-Ping Wang
Evolution of COVID-19 antiviral interventions in Taiwan, 2022-2025: Insights from public health policy [0.03%]
台湾地区2022至2025年COVID-19抗病毒干预措施的演变:公共卫生政策的启示
Hsin-Yi Wei,Chien-Yu Lin,Yu-Jing Lin et al.
Hsin-Yi Wei et al.
This study reviewed the use of COVID-19 antiviral agents in Taiwan (2022-2025), focusing on how policy changes influenced drug deployment, and explored trends in outpatient visits, hospitalizations, emergency department visits, and mortalit...
Response to comments on "Effectiveness of amivantamab compared with real-world therapies in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations post platinum-based chemotherapy" [0.03%]
关于“氨磺必利与铂基化疗后非小细胞肺癌EGFR 20外显子插入突变患者现实世界治疗方案的有效性比较”的评论回应
Jenn-Yu Wu,Jianmin Zhuo,Ji-Fan Hsieh et al.
Jenn-Yu Wu et al.
Comment on "Language and motor plasticity as predictors of preschool intelligence: methodological considerations and clinical implications" [0.03%]
“语言和运动可塑性作为学龄前智力预测因素的方法学考量及临床意义”评论
Jiale Zhang,Chen Chen,Ya Luo
Jiale Zhang